Newcastle disease virus: Current status and our understanding

Virus Research

Volumn 184, Issue , 2014, Pages 71-81

  Ganar, Ketan ^a   Das, Moushumee ^a   Sinha, Sugandha ^a   Kumar, Sachin ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY GUWAHATI   (India)

Author keywords

Newcastle disease virus; Paramyxovirus; Pathogenicity; Reverse genetics system

Indexed keywords

DIHYDROLIPOAMIDE DEHYDROGENASE; HN PROTEIN; HYBRID PROTEIN; LIVE VACCINE; MATRIX PROTEIN; NEWCASTLE DISEASE PARAMYXOVIRUS VACCINE; NUCLEOCAPSID PROTEIN; ONCOLYTIC VIRUS; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PHOSPHOPROTEIN; VIRUS PROTEIN; VIRUS PROTEIN V; DRUG CARRIER;

DNA REPLICATION; GENETIC RECOMBINATION; HUMAN; MOLECULAR BIOLOGY; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; VIRUS GENOME; VIRUS REPLICATION; VIRUS VIRULENCE; ANIMAL; BIOLOGICAL THERAPY; BIRD; BIRD DISEASE; GENE VECTOR; GENETICS; NEWCASTLE DISEASE VIRUS; PHYSIOLOGY; PROCEDURES; VIROLOGY;

ANIMALS; BIOLOGICAL THERAPY; BIRD DISEASES; BIRDS; DRUG CARRIERS; GENETIC VECTORS; HUMANS; NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIRUSES;

EID: 84898621428     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2014.02.016     Document Type: Review

References (145)

1. Anon. Vaccination Against Newcastle Disease 2013, Department of Primary Industries Parks Water and Environment.
2. Alamares J.G., Elankumaran S., Samal S.K., Iorio R.M. The interferon antagonistic activities of the V proteins from two strains of Newcastle disease virus correlate with their known virulence properties. Virus Res. 2010, 147(1):153-157.
3. Albiston H., Gorrie C. Newcastle disease on Victoria. Aust. Vet. J. 1942, 18:75-79.
4. Alexander D.J. Newcastle disease and other avian paramyxoviruses. A Laboratory Manual for the Isolation and Identification of Avian Pathogens 1998, American Association of Avian Pathologists, Philadelphia. 4th ed. D.E. Swayne, J. Glisson, M.W. Jackwood, J.E. Pearson, W.M. Reed (Eds.).
5. Alexander D.J. Newcastle disease and other avian paramyxoviruses. Rev. Sci. Tech. 2000, 19(2):443-462.
6. Altomonte J., Marozin S., Schmid R.M., Ebert O. Engineered Newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol. Ther. 2010, 18(2):275-284.
7. Batliwalla F.M., Bateman B.A., Serrano D., Murray D., Macphail S., Maino V.C., Ansel J.C., Gregersen P.K., Armstrong C.A. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8T cell repertoire. Mol. Med. 1998, 4(12):783-794.
8. Biswas M., Johnson J.B., Kumar S.R., Parks G.D., Elankumarana S. Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion. J. Virol. 2012, 86(23):12708-12716.
9. Bukreyev A., Collins P.L. Newcastle disease virus as a vaccine vector for humans. Curr. Opin. Mol. Ther. 2008, 10(1):46-55.
10. Bukreyev A., Huang Z., Yang L., Elankumaran S., St Claire M., Murphy B.R., Samal S.K., Collins P.L. Recombinant Newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J. Virol. 2005, 79(21):13275-13284.
11. Bukreyev A., Skiadopoulos M.H., Murphy B.R., Collins P.L. Nonsegmented negative-strand viruses as vaccine vectors. J. Virol. 2006, 80(21):10293-10306.
12. Calain P., Roux L. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J. Virol. 1993, 67(8):4822-4830.
13. Cantin C., Holguera J., Ferreira L., Villar E., Munoz-Barroso I. Newcastle disease virus may enter cells by caveolae-mediated endocytosis. J. Gen. Virol. 2007, 88(Pt 2):559-569.
14. Carnero E., Li W., Borderia A.V., Moltedo B., Moran T., Garcia-Sastre A. Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses. J. Virol. 2009, 83(2):584-597.
15. Cassel W.A., Garrett R.E. Newcastle disease virus as an antineoplastic agent. Cancer 1965, 18:863-868.
16. Ch'ng W.C., Stanbridge E.J., Yusoff K., Shafee N. The oncolytic activity of Newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: the interplay between von Hippel-Lindau and interferon-beta signaling. J. Interferon Cytokine Res. 2013, 33(7):346-354.
17. Chambers P., Millar N.S., Platt S.G., Emmerson P.T. Nucleotide sequence of the gene encoding the matrix protein of Newcastle disease virus. Nucleic Acids Res. 1986, 14(22):9051-9061.
18. Chen F., Liu J., Liu D., Yan Z., Ji J., Qin J., Li H., Ma J., Bi Y., Xie Q. Complete genome sequence of a Newcastle disease virus strain isolated from broiler breeder flocks in China. J. Virol. 2012, 86(22):12461-12462.
19. Chen S., Hao H., Wang X., Du E., Liu H., Yang T., Liu Y., Fu X., Zhang P., Yang Z. Genomic characterisation of a lentogenic Newcastle disease virus strain HX01 isolated from sick pigs in China. Virus Genes 2013, 46(2):264-270.
20. Choi K.S., Kye S.J., Kim J.Y., To T.L., Nguyen D.T., Lee Y.J., Choi J.G., Kang H.M., Kim K.I., Song B.M., Lee H.S. Molecular epidemiology of Newcastle disease viruses in Vietnam. Trop. Anim. Health Prod. 2014, 46(1):271-277.
21. Corey E.A., Mirza A.M., Levandowsky E., Iorio R.M. Fusion deficiency induced by mutations at the dimer interface in the Newcastle disease virus hemagglutinin-neuraminidase is due to a temperature-dependent defect in receptor binding. J. Virol. 2003, 77(12):6913-6922.
22. Cornax I., Diel D.G., Rue C.A., Estevez C., Yu Q., Miller P.J., Afonso C.L. Newcastle disease virus fusion and haemagglutinin-neuraminidase proteins contribute to its macrophage host range. J. Gen. Virol. 2013, 94(Pt 6):1189-1194.
23. Cornelissen L.A., de Vries R.P., de Boer-Luijtze E.A., Rigter A., Rottier P.J., de Haan C.A. A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1. PLoS ONE 2010, 5(5):e10645.
24. Crawford M. Rannikhet. Ann. Rept. 1930, Govt. Vet. Surgeon, Colombo, Ceylon.
25. Czegledi A., Ujvari D., Somogyi E., Wehmann E., Werner O., Lomniczi B. Third genome size category of avian paramyxovirus serotype 1 (Newcastle disease virus) and evolutionary implications. Virus Res. 2006, 120(1-2):36-48.
26. de Leeuw O., Peeters B. Complete nucleotide sequence of Newcastle disease virus: evidence for the existence of a new genus within the subfamily Paramyxovirinae. J. Gen. Virol. 1999, 80(Pt 1):131-136.
27. de Leeuw O.S., Koch G., Hartog L., Ravenshorst N., Peeters B.P. Virulence of Newcastle disease virus is determined by the cleavage site of the fusion protein and by both the stem region and globular head of the haemagglutinin-neuraminidase protein. J. Gen. Virol. 2005, 86(Pt 6):1759-1769.
28. Deng R., Wang Z., Mirza A.M., Iorio R.M. Localization of a domain on the paramyxovirus attachment protein required for the promotion of cellular fusion by its homologous fusion protein spike. Virology 1995, 209(2):457-469.
29. Diel D.G., Miller P.J., Wolf P.C., Mickley R.M., Musante A.R., Emanueli D.C., Shively K.J., Pedersen K., Afonso C.L. Characterization of Newcastle disease viruses isolated from cormorant and gull species in the United States in 2010. Avian Dis. 2012, 56(1):128-133.
30. DiNapoli J.M., Kotelkin A., Yang L., Elankumaran S., Murphy B.R., Samal S.K., Collins P.L., Bukreyev A. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(23):9788-9793.
31. DiNapoli J.M., Nayak B., Yang L., Finneyfrock B.W., Cook A., Andersen H., Torres-Velez F., Murphy B.R., Samal S.K., Collins P.L., Bukreyev A. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J. Virol. 2010, 84(3):1489-1503.
32. Dortmans J.C., Koch G., Rottier P.J., Peeters B.P. Virulence of Newcastle disease virus: what is known so far?. Vet. Res. 2011, 42:122-130.
33. Dortmans J.C., Rottier P.J., Koch G., Peeters B.P. The viral replication complex is associated with the virulence of Newcastle disease virus. J. Virol. 2010, 84(19):10113-10120.
34. Doyle T. A hitherto unrecorded disease of fowls due to filter passing virus. J. Comp. Pathol. Therap. 1927, 144-169.
35. Edwards J. A New Fowl Disease 1928, Vet. Res. Mukteshwar, March 31st, pp. 14-15.
36. Elankumaran S. Genetically engineered Newcastle disease virus for prostate cancer: a magic bullet or a misfit. Expert Rev. Anticancer Ther. 2013, 13(7):769-772.
37. Elankumaran S., Chavan V., Qiao D., Shobana R., Moorkanat G., Biswas M., Samal S.K. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy. J. Virol. 2010, 84(8):3835-3844.
38. Elankumaran S., Rockemann D., Samal S.K. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J. Virol. 2006, 80(15):7522-7534.
39. Errington W., Emmerson P.T. Assembly of recombinant Newcastle disease virus nucleocapsid protein into nucleocapsid-like structures is inhibited by the phosphoprotein. J. Gen. Virol. 1997, 78(Pt 9):2335-2339.
40. Ferreira H.L., Pirlot J.F., Reynard F., van den Berg T., Bublot M., Lambrecht B. Immune responses and protection against H5N1 highly pathogenic avian influenza virus induced by the Newcastle disease virus H5 vaccine in ducks. Avian Dis. 2012, 56(4 Suppl.):940-948.
41. Forrester N.L., Widen S.G., Wood T.G., Travassos da Rosa A.P., Ksiazek T.G., Vasilakis N., Tesh R.B. Identification of a new Newcastle disease virus isolate from Indonesia represents an ancestral lineage of class II genotype XIII. Virus Genes 2013, 47(1):168-172.
42. Freeman A.I., Zakay-Rones Z., Gomori J.M., Linetsky E., Rasooly L., Greenbaum E., Rozenman-Yair S., Panet A., Libson E., Irving C.S., Galun E., Siegal T. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther. 2006, 13(1):221-228.
43. Ge J., Deng G., Wen Z., Tian G., Wang Y., Shi J., Wang X., Li Y., Hu S., Jiang Y., Yang C., Yu K., Bu Z., Chen H. Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J. Virol. 2007, 81(1):150-158.
44. Ghrici M., El Zowalaty M., Omar A.R., Ideris A. Induction of apoptosis in MCF-7 cells by the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus Malaysian strain AF2240. Oncol. Rep. 2013, 30(3):1035-1044.
45. Glickman R.L., Syddall R.J., Iorio R.M., Sheehan J.P., Bratt M.A. Quantitative basic residue requirements in the cleavage-activation site of the fusion glycoprotein as a determinant of virulence for Newcastle disease virus. J. Virol. 1988, 62(1):354-356.
46. Gorman J.J., Nestorowicz A., Mitchell S.J., Corino G.L., Selleck P.W. Characterization of the sites of proteolytic activation of Newcastle disease virus membrane glycoprotein precursors. J. Biol. Chem. 1988, 263(25):12522-12531.
47. Haddas R., Meir R., Perk S., Horowitz I., Lapin E., Rosenbluth E., Lublin A. Newcastle disease virus in Little Owls (Athene noctua) and African Penguins (Spheniscus demersus) in an Israeli Zoo. Transbound Emerg. Dis. 2013, 10.1111/tbed.12064.
48. Horikami S.M., Smallwood S., Moyer S.A. The Sendai virus V protein interacts with the NP protein to regulate viral genome RNA replication. Virology 1996, 222(2):383-390.
49. Hotte S.J., Lorence R.M., Hirte H.W., Polawski S.R., Bamat M.K., O'Neil J.D., Roberts M.S., Groene W.S., Major P.P. An optimized clinical regimen for the oncolytic virus PV701. Clin. Cancer Res. 2007, 13(3):977-985.
50. Hu X.L., Ray R., Compans R.W. Functional interactions between the fusion protein and hemagglutinin-neuraminidase of human parainfluenza viruses. J. Virol. 1992, 66(3):1528-1534.
51. Huang Y., Wan H.Q., Liu H.Q., Wu Y.T., Liu X.F. Genomic sequence of an isolate of Newcastle disease virus isolated from an outbreak in geese: a novel six nucleotide insertion in the non-coding region of the nucleoprotein gene. Brief report. Arch. Virol. 2004, 149(7):1445-1457.
52. Huang Z., Elankumaran S., Panda A., Samal S.K. Recombinant Newcastle disease virus as a vaccine vector. Poult. Sci. 2003, 82(6):899-906.
53. Huang Z., Elankumaran S., Yunus A.S., Samal S.K. A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV. J. Virol. 2004, 78(18):10054-10063.
54. Huang Z., Krishnamurthy S., Panda A., Samal S.K. High-level expression of a foreign gene from the most 3'-proximal locus of a recombinant Newcastle disease virus. J. Gen. Virol. 2001, 82(Pt 7):1729-1736.
55. Huang Z., Krishnamurthy S., Panda A., Samal S.K. Newcastle disease virus V protein is associated with viral pathogenesis and functions as an alpha interferon antagonist. J. Virol. 2003, 77(16):8676-8685.
56. Huang Z., Panda A., Elankumaran S., Govindarajan D., Rockemann D.D., Samal S.K. The hemagglutinin-neuraminidase protein of Newcastle disease virus determines tropism and virulence. J. Virol. 2004, 78(8):4176-4184.
57. Iorio R.M., Glickman R.L., Riel A.M., Sheehan J.P., Bratt M.A. Functional and neutralization profile of seven overlapping antigenic sites on the HN glycoprotein of Newcastle disease virus: monoclonal antibodies to some sites prevent viral attachment. Virus Res. 1989, 13(3):245-261.
58. Iorio R.M., Mahon P.J. Paramyxoviruses: different receptors - different mechanisms of fusion. Trends Microbiol. 2008, 16(4):135-137.
59. Jahanshiri F., Eshaghi M., Yusoff K. Identification of phosphoprotein:phosphoprotein and phosphoprotein:nucleocapsid protein interaction domains of the Newcastle disease virus. Arch. Virol. 2005, 150(3):611-618.
60. Janke M., Peeters B., de Leeuw O., Moorman R., Arnold A., Fournier P., Schirrmacher V. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther. 2007, 14(23):1639-1649.
61. Kaleta E., Baldauf C. Newcastle disease in free-living and pet birds. Newcastle Disease 1988, Kluwer Acedemic Press, Boston, MA. D.J. Alexander (Ed.).
62. Kanno T., Ochi Y., Hashimoto K. Neue Geflugelscuche in Korea 1929, Dtsch. Tierarzhl. Wshr.
63. Kattenbelt J.A., Stevens M.P., Gould A.R. Sequence variation in the Newcastle disease virus genome. Virus Res. 2006, 116(1-2):168-184.
64. Khattar S.K., Collins P.L., Samal S.K. Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1. Vaccine 2010, 28(18):3159-3170.
65. Khattar S.K., Samal S., Devico A.L., Collins P.L., Samal S.K. Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs. J. Virol. 2011, 85(20):10529-10541.
66. Khattar S.K., Samal S., Labranche C.C., Montefiori D.C., Collins P.L., Samal S.K. Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector. PLoS ONE 2013, 8(10):e78521.
67. Khattar S.K., Yan Y., Panda A., Collins P.L., Samal S.K. A Y526Q mutation in the Newcastle disease virus HN protein reduces its functional activities and attenuates virus replication and pathogenicity. J. Virol. 2009, 83(15):7779-7782.
68. Kho C.L., Tan W.S., Tey B.T., Yusoff K. Newcastle disease virus nucleocapsid protein: self-assembly and length-determination domains. J. Gen. Virol. 2003, 84(Pt 8):2163-2168.
69. Kim S.H., Xiao S., Paldurai A., Collins P.L., Samal S.K. Role of C596 in the C-terminal extension of the haemagglutinin-neuraminidase protein in replication and pathogenicity of a highly virulent Indonesian strain of Newcastle disease virus. J. Gen. Virol. 2014, 95(Pt 2):331-336.
70. Kim S.H., Yan Y., Samal S.K. Role of the cytoplasmic tail amino acid sequences of Newcastle disease virus hemagglutinin-neuraminidase protein in virion incorporation, cell fusion, and pathogenicity. J. Virol. 2009, 83(19):10250-10255.
71. Kong D., Wen Z., Su H., Ge J., Chen W., Wang X., Wu C., Yang C., Chen H., Bu Z. Newcastle disease virus-vectored Nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs. Virology 2012, 432(2):327-335.
72. Kortekaas J., de Boer S.M., Kant J., Vloet R.P., Antonis A.F., Moormann R.J. Rift valley fever virus immunity provided by a paramyxovirus vaccine vector. Vaccine 2010, 28(27):4394-4401.
73. Kraneveld F. Over een in Ned-Indie heerschende Ziete under het pluimves. Ned. Indisch Bl. Diergeneesk. 1926, 38:448-450.
74. Krishnamurthy S., Huang Z., Samal S.K. Recovery of a virulent strain of Newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation. Virology 2000, 278(1):168-182.
75. Krishnamurthy S., Samal S.K. Nucleotide sequences of the trailer, nucleocapsid protein gene and intergenic regions of Newcastle disease virus strain Beaudette C and completion of the entire genome sequence. J. Gen. Virol. 1998, 79(Pt 10):2419-2424.
76. Kumar S., Nayak B., Collins P.L., Samal S.K. Evaluation of the Newcastle disease virus F and HN proteins in protective immunity by using a recombinant avian paramyxovirus type 3 vector in chickens. J. Virol. 2011, 85(13):6521-6534.
77. Lam H.Y., Yeap S.K., Rasoli M., Omar A.R., Yusoff K., Suraini A.A., Alitheen N.B. Safety and clinical usage of newcastle disease virus in cancer therapy. J. Biomed. Biotechnol. 2011, 2011:718710.
78. Lamb R., Parks G. Paramyxoviridae: the viruses and their replication. Fields Virology 2007, 1449-1496. Lippincott Williams & Wilkins, Philadelphia. 5th ed. D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb, M.A. Martin, B. Roizman, S.E. Straus (Eds.).
79. Lawrence T.M., Wanjalla C.N., Gomme E.A., Wirblich C., Gatt A., Carnero E., Garcia-Sastre A., Lyles D.S., McGettigan J.P., Schnell M.J. Comparison of heterologous prime-boost strategies against human immunodeficiency virus type 1 gag using negative stranded RNA viruses. PLoS ONE 2013, 8(6):e67123.
80. Lindh E., Ek-Kommonen C., Vaananen V.M., Alasaari J., Vaheri A., Vapalahti O., Huovilainen A. Molecular epidemiology of outbreak-associated and wild-waterfowl-derived newcastle disease virus strains in Finland, including a novel class I genotype. J. Clin. Microbiol. 2012, 50(11):3664-3673.
81. Liu H., Zhang P., Wu P., Chen S., Mu G., Duan X., Hao H., Du E., Wang X., Yang Z. Phylogenetic characterization and virulence of two Newcastle disease viruses isolated from wild birds in China. Infect. Genet. Evol. 2013, 20C:215-224.
82. Lorence R.M., Katubig B.B., Reichard K.W., Reyes H.M., Phuangsab A., Sassetti M.D., Walter R.J., Peeples M.E. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res. 1994, 54(23):6017-6021.
83. Lorence R.M., Pecora A.L., Major P.P., Hotte S.J., Laurie S.A., Roberts M.S., Groene W.S., Bamat M.K. Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr. Opin. Mol. Ther. 2003, 5(6):618-624.
84. Martinez-Sobrido L., Gitiban N., Fernandez-Sesma A., Cros J., Mertz S.E., Jewell N.A., Hammond S., Flano E., Durbin R.K., Garcia-Sastre A., Durbin J.E. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J. Virol. 2006, 80(3):1130-1139.
85. McGinnes L.W., Morrison T.G. The role of the individual cysteine residues in the formation of the mature, antigenic HN protein of Newcastle disease virus. Virology 1994, 200(2):470-483.
86. Mebatsion T., Koolen M.J., de Vaan L.T., de Haas N., Braber M., Romer-Oberdorfer A., van den Elzen P., van der Marel P. Newcastle disease virus (NDV) marker vaccine: an immunodominant epitope on the nucleoprotein gene of NDV can be deleted or replaced by a foreign epitope. J. Virol. 2002, 76(20):10138-10146.
87. Mebatsion T., Weiland F., Conzelmann K.K. Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G. J. Virol. 1999, 73(1):242-250.
88. Melanson V.R., Iorio R.M. Amino acid substitutions in the F-specific domain in the stalk of the Newcastle disease virus HN protein modulate fusion and interfere with its interaction with the F protein. J. Virol. 2004, 78(23):13053-13061.
89. Mirza A.M., Iorio R.M. A mutation in the stalk of the newcastle disease virus hemagglutinin-neuraminidase (HN) protein prevents triggering of the F protein despite allowing efficient HN-F complex formation. J. Virol. 2013, 87(15):8813-8815.
90. Molouki A., Yusoff K. NDV-induced apoptosis in absence of Bax; evidence of involvement of apoptotic proteins upstream of mitochondria. Virol. J. 2012, 9:179.
91. Morrison T.G. Structure and function of a paramyxovirus fusion protein. Biochim. Biophys. Acta 2003, 1614(1):73-84.
92. Nagai Y., Klenk H.D., Rott R. Proteolytic cleavage of the viral glycoproteins and its significance for the virulence of Newcastle disease virus. Virology 1976, 72(2):494-508.
93. Nakaya T., Cros J., Park M.S., Nakaya Y., Zheng H., Sagrera A., Villar E., Garcia-Sastre A., Palese P. Recombinant Newcastle disease virus as a vaccine vector. J. Virol. 2001, 75(23):11868-11873.
94. Nakaya Y., Nakaya T., Park M.S., Cros J., Imanishi J., Palese P., Garcia-Sastre A. Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors. J. Virol. 2004, 78(17):9366-9375.
95. Nayak B., Rout S.N., Kumar S., Khalil M.S., Fouda M.M., Ahmed L.E., Earhart K.C., Perez D.R., Collins P.L., Samal S.K. Immunization of chickens with Newcastle disease virus expressing H5 hemagglutinin protects against highly pathogenic H5N1 avian influenza viruses. PLoS ONE 2009, 4(8):e6509.
96. Ochi Y., Hashimoto K. Uber eine neue Geflugelseuche in Korea. 6th Rept. 1929, Govt. Inst. Vet. Research (Chosen), August 20th, 16 pp.
97. Panda A., Huang Z., Elankumaran S., Rockemann D.D., Samal S.K. Role of fusion protein cleavage site in the virulence of Newcastle disease virus. Microb. Pathog. 2004, 36(1):1-10.
98. Pantua H.D., McGinnes L.W., Peeples M.E., Morrison T.G. Requirements for the assembly and release of Newcastle disease virus-like particles. J. Virol. 2006, 80(22):11062-11073.
99. Park M.S., Garcia-Sastre A., Cros J.F., Basler C.F., Palese P. Newcastle disease virus V protein is a determinant of host range restriction. J. Virol. 2003, 77(17):9522-9532.
100. Park M.S., Steel J., Garcia-Sastre A., Swayne D., Palese P. Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(21):8203-8208.
101. Peeples M.E., Bratt M.A. Mutation in the matrix protein of Newcastle disease virus can result in decreased fusion glycoprotein incorporation into particles and decreased infectivity. J. Virol. 1984, 51(1):81-90.
102. Peeters B.P., de Leeuw O.S., Koch G., Gielkens A.L. Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J. Virol. 1999, 73(6):5001-5009.
103. Peeters B.P., de Leeuw O.S., Verstegen I., Koch G., Gielkens A.L. Generation of a recombinant chimeric Newcastle disease virus vaccine that allows serological differentiation between vaccinated and infected animals. Vaccine 2001, 19(13-14):1616-1627.
104. Pelet T., Delenda C., Gubbay O., Garcin D., Kolakofsky D. Partial characterization of a Sendai virus replication promoter and the rule of six. Virology 1996, 224(2):405-414.
105. Puhler F., Willuda J., Puhlmann J., Mumberg D., Romer-Oberdorfer A., Beier R. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes. Gene Ther. 2008, 15(5):371-383.
106. Ravindra P.V., Tiwari A.K., Ratta B., Chaturvedi U., Palia S.K., Subudhi P.K., Kumar R., Sharma B., Rai A., Chauhan R.S. Induction of apoptosis in Vero cells by Newcastle disease virus requires viral replication, de-novo protein synthesis and caspase activation. Virus Res. 2008, 133(2):285-290.
107. Ravindra P.V., Tiwari A.K., Sharma B., Chauhan R.S. Newcastle disease virus as an oncolytic agent. Indian J. Med. Res. 2009, 130(5):507-513.
108. Ravindra P.V., Tiwari A.K., Sharma B., Rajawat Y.S., Ratta B., Palia S., Sundaresan N.R., Chaturvedi U., Kumar G.B., Chindera K., Saxena M., Subudhi P.K., Rai A., Chauhan R.S. HN protein of Newcastle disease virus causes apoptosis in chicken embryo fibroblast cells. Arch. Virol. 2008, 153(4):749-754.
109. Reichard K.W., Lorence R.M., Cascino C.J., Peeples M.E., Walter R.J., Fernando M.B., Reyes H.M., Greager J.A. Newcastle disease virus selectively kills human tumor cells. J. Surg. Res. 1992, 52(5):448-453.
110. Rodier E. Philippines fowl disease. Proc. Soc. Exp. Biol. Med. 1928, 25:781-783.
111. Romer-Oberdorfer A., Mundt E., Mebatsion T., Buchholz U.J., Mettenleiter T.C. Generation of recombinant lentogenic Newcastle disease virus from cDNA. J. Gen. Virol. 1999, 80(Pt 11):2987-2995.
112. Romer-Oberdorfer A., Veits J., Helferich D., Mettenleiter T.C. Level of protection of chickens against highly pathogenic H5 avian influenza virus with Newcastle disease virus based live attenuated vector vaccine depends on homology of H5 sequence between vaccine and challenge virus. Vaccine 2008, 26(19):2307-2313.
113. Romer-Oberdorfer A., Werner O., Veits J., Mebatsion T., Mettenleiter T.C. Contribution of the length of the HN protein and the sequence of the F protein cleavage site to Newcastle disease virus pathogenicity. J. Gen. Virol. 2003, 84(Pt 11):3121-3129.
114. Rout S.N., Samal S.K. The large polymerase protein is associated with the virulence of Newcastle disease virus. J. Virol. 2008, 82(16):7828-7836.
115. Sakaguchi T., Fujii Y., Kiyotani K., Yoshida T. Correlation of proteolytic cleavage of F protein precursors in paramyxoviruses with expression of the fur, PACE4 and PC6 genes in mammalian cells. J. Gen. Virol. 1994, 75(Pt 10):2821-2827.
116. Samal S., Khattar S.K., Kumar S., Collins P.L., Samal S.K. Coordinate deletion of N-glycans from the heptad repeats of the fusion F protein of Newcastle disease virus yields a hyperfusogenic virus with increased replication, virulence, and immunogenicity. J. Virol. 2012, 86(5):2501-2511.
117. Samal S., Khattar S.K., Paldurai A., Palaniyandi S., Zhu X., Collins P.L., Samal S.K. Mutations in the cytoplasmic domain of the Newcastle disease virus fusion protein confer hyperfusogenic phenotypes modulating viral replication and pathogenicity. J. Virol. 2013, 87(18):10083-10093.
118. Samal S., Kumar S., Khattar S.K., Samal S.K. A single amino acid change, Q114R, in the cleavage-site sequence of Newcastle disease virus fusion protein attenuates viral replication and pathogenicity. J. Gen. Virol. 2011, 92(Pt 10):2333-2338.
119. Samal S.K. Newcastle Disease and Related Avian Paramyxoviruses. Vol. I. The Biology of Paramyxoviruses 2011, Caister Academic Press, Norfolk, United Kingdom. S.K. Samal (Ed.).
120. Sanchez-Felipe L., Villar E., Munoz-Barroso I. Entry of Newcastle disease virus into the host cell: role of acidic pH and endocytosis. Biochim. Biophys. Acta 2014, 1838(1):300-309.
121. Schirrmacher V., Griesbach A., Ahlert T. Antitumor effects of Newcastle disease virus in vivo: local versus systemic effects. Int. J. Oncol. 2001, 18(5):945-952.
122. Schroer D., Veits J., Grund C., Dauber M., Keil G., Granzow H., Mettenleiter T.C., Romer-Oberdorfer A. Vaccination with Newcastle disease virus vectored vaccine protects chickens against highly pathogenic H7 avian influenza virus. Avian Dis. 2009, 53(2):190-197.
123. Seal B.S., King D.J., Meinersmann R.J. Molecular evolution of the Newcastle disease virus matrix protein gene and phylogenetic relationships among the paramyxoviridae. Virus Res. 2000, 66(1):1-11.
124. Sergel T., McGinnes L.W., Morrison T.G. The fusion promotion activity of the NDV HN protein does not correlate with neuraminidase activity. Virology 1993, 196(2):831-834.
125. Sergel T., McGinnes L.W., Peeples M.E., Morrison T.G. The attachment function of the Newcastle disease virus hemagglutinin-neuraminidase protein can be separated from fusion promotion by mutation. Virology 1993, 193(2):717-726.
126. Sharma B., Pokhriyal M., Rai G.K., Saxena M., Ratta B., Chaurasia M., Yadav B.S., Sen A., Mondal B. Isolation of Newcastle disease virus from a non-avian host (sheep) and its implications. Arch. Virol. 2012, 157(8):1565-1567.
127. Sheehan J.P., Iorio R.M. A single amino acid substitution in the hemagglutinin-neuraminidase of Newcastle disease virus results in a protein deficient in both functions. Virology 1992, 189(2):778-781.
128. Shobana R., Samal S.K., Elankumaran S. Prostate-specific antigen-retargeted recombinant Newcastle disease virus for prostate cancer virotherapy. J. Virol. 2013, 87(7):3792-3800.
129. Snoeck C.J., Owoade A.A., Couacy-Hymann E., Alkali B.R., Okwen M.P., Adeyanju A.T., Komoyo G.F., Nakoune E., Le Faou A., Muller C.P. High genetic diversity of Newcastle disease virus in poultry in West and Central Africa: cocirculation of genotype XIV and newly defined genotypes XVII and XVIII. J. Clin. Microbiol. 2013, 51(7):2250-2260.
130. Steward M., Vipond I.B., Millar N.S., Emmerson P.T. RNA editing in Newcastle disease virus. J. Gen. Virol. 1993, 74(Pt 12):2539-2547.
131. Stojdl D.F., Lichty B., Knowles S., Marius R., Atkins H., Sonenberg N., Bell J.C. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 2000, 6(7):821-825.
132. Stone-Hulslander J., Morrison T.G. Detection of an interaction between the HN and F proteins in Newcastle disease virus-infected cells. J. Virol. 1997, 71(9):6287-6295.
133. Stone-Hulslander J., Morrison T.G. Mutational analysis of heptad repeats in the membrane-proximal region of Newcastle disease virus HN protein. J. Virol. 1999, 73(5):3630-3637.
134. Swayne D.E., King D.J. Avian influenza and Newcastle disease. J. Am. Vet. Med. Assoc. 2003, 222(11):1534-1540.
135. Ten R.M., Blank V., Le Bail O., Kourilsky P., Israel A. Two factors, IRF1 and KBF1/NF-kappa B, cooperate during induction of MHC class I gene expression by interferon alpha beta or Newcastle disease virus. C. R. Acad. Sci. III 1993, 316(5):496-501.
136. Tolf C., Wille M., Haidar A.K., Avril A., Zohari S., Waldenstrom J. Prevalence of avian paramyxovirus type 1 in Mallards during autumn migration in the western Baltic Sea region. Virol. J. 2013, 10(1):285.
137. Tong S., Compans R.W. Alternative mechanisms of interaction between homotypic and heterotypic parainfluenza virus HN and F proteins. J. Gen. Virol. 1999, 80(Pt 1):107-115.
138. Toyoda T., Sakaguchi T., Imai K., Inocencio N.M., Gotoh B., Hamaguchi M., Nagai Y. Structural comparison of the cleavage-activation site of the fusion glycoprotein between virulent and avirulent strains of Newcastle disease virus. Virology 1987, 158(1):242-247.
139. Vigil A., Park M.S., Martinez O., Chua M.A., Xiao S., Cros J.F., Martinez-Sobrido L., Woo S.L., Garcia-Sastre A. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res. 2007, 67(17):8285-8292.
140. Westbury H. Newcastle disease virus: an evolving pathogen?. Avian Pathol. 2001, 30(1):5-11.
141. Xie Z., Xie L., Chen A., Liu J., Pang Y., Deng X., Fan Q. Complete genome sequence analysis of a Newcastle disease virus isolated from a wild egret. J. Virol. 2012, 86(24):13854-13855.
142. Yan Y., Rout S.N., Kim S.H., Samal S.K. Role of untranslated regions of the hemagglutinin-neuraminidase gene in replication and pathogenicity of newcastle disease virus. J. Virol. 2009, 83(11):5943-5946.
143. Zamarin D., Martinez-Sobrido L., Kelly K., Mansour M., Sheng G., Vigil A., Garcia-Sastre A., Palese P., Fong Y. Enhancement of oncolytic properties of recombinant Newcastle disease virus through antagonism of cellular innate immune responses. Mol. Ther. 2009, 17(4):697-706.
144. Zhang Z.Y., Wang L.Q., Fu C.F., Li X., Cui Z.L., Zhang J.Y., Xue S.H., Sun N., Xu F. Combination of targeting gene-viro therapy with recombinant Fowl-pox viruses with HN and VP3 genes on mouse osteosarcoma. Eur. Rev. Med. Pharmacol. Sci. 2013, 17(6):767-776.
145. Zhao W., Hu H., Zsak L., Yu Q., Yang Z. HN gene C-terminal extension of Newcastle disease virus is not the determinant of the enteric tropism. Virus Genes 2013, 47(1):27-33.